Data on the real-world effectiveness and impact of the COVID-19 vaccines.
Related Organizations
- Published in
- United Kingdom
Table of Contents
- COVID-19 vaccine surveillance report 1
- Week 41 1
- 12 October 2023 1
- Contents 2
- Executive summary 3 2
- Vaccine effectiveness 4 2
- Effectiveness against symptomatic disease 4 2
- Effectiveness against hospitalisation 4 2
- Long-term duration of protection of monovalent vaccines 4 2
- Effectiveness of the autumn 2022 bivalent booster 5 2
- Effectiveness of the spring 2023 bivalent booster 6 2
- Effectiveness against mortality (vaccines given prior to the autumn 2022 bivalent boosters) 7 2
- Consensus vaccine effectiveness estimates 9 2
- Effectiveness against XBB.1.5, CH.1.1 and BQ.1 11 2
- Vaccine effectiveness publications 12 2
- Population impact 13 2
- Vaccination in pregnancy 13 2
- Estimation of hospitalisations averted from the autumn 2022 bivalent booster programme 21 2
- Vaccine impact on proportion of population with antibodies to COVID-19 23 2
- Seroprevalence 23 2
- References 32 2
- About the UK Health Security Agency 35 2
- Executive summary 3
- Vaccine effectiveness 4
- Effectiveness against symptomatic disease 4
- Effectiveness against hospitalisation 4
- Long-term duration of protection of monovalent vaccines 4
- Table 1. Absolute vaccine effectiveness (VE) against hospitalisation of a second or at least a third dose of the monovalent vaccines amongst those aged 18 to 64 and those aged 65 years and older 5
- Effectiveness of the autumn 2022 bivalent booster 5
- Table 2. Vaccine effectiveness of the bivalent booster vaccines against hospitalisation in those aged 50 years and older (VE = vaccine effectiveness, CI = confidence intervals) 6
- Effectiveness of the spring 2023 bivalent booster 6
- Table 3. Vaccine effectiveness (VE) against hospitalisation amongst those aged 75 years and older in England, stratified by spring booster manufacturer 7
- Effectiveness against mortality (vaccines given prior to the autumn 2022 bivalent boosters) 7
- Table 4. Vaccine effectiveness against mortality in those aged 65 years and older (all vaccine brands combined) (VE = vaccine effectiveness, CI = confidence intervals) 8
- Consensus vaccine effectiveness estimates 9
- Table 5. Consensus estimates of incremental vaccine effectiveness of the autumn 2022 booster programme and earlier monovalent booster doses 9
- Table 6. Consensus estimates of incremental vaccine effectiveness of the spring 2023 booster programme 10
- These results relate to a period when XBB Omicron sublineages were circulating and are relative to 3+ months since the autumn 2022 booster. 10
- Effectiveness against XBB.1.5, CH.1.1 and BQ.1 11
- Table 7. VE estimates against hospitalisation with XBB.1.5, CH.1.1 and BQ.1 for the bivalent boosters in those aged 50 years and older 11
- Vaccine effectiveness publications 12
- Table 8. UKHSA publications on the effectiveness of COVID-19 vaccination 12
- Population impact 13
- Vaccination in pregnancy 13
- Vaccine coverage 15
- Figure 1. Women who gave birth between September 2022 and June 2023 and those who received an autumn 2022 COVID-19 dose prior to delivery 17
- Table 9. Vaccine coverage in women giving birth between September 2022 (when the Autumn boost was first offered) and June 2023 by age group, ethnicity and quintile of deprivation (where 1 is most deprived and 5 is most affluent) [note 1] [note 2] 18
- Methods 18
- Interpretation and limitations 20
- Main findings 20
- Estimation of hospitalisations averted from the autumn 2022 bivalent booster programme 21
- Figure 2. Observed COVID-19 hospitalisation and the estimated number averted from vaccination by week autumn to winter 2022 to 2023, aged 50 and over 22
- Vaccine impact on proportion of population with antibodies to COVID-19 23
- Seroprevalence 23
- Seroprevalence in blood donors aged 17 years and older 23
- National prevalence 24
- Figure 3. Overall 12-weekly rolling SARS-CoV-2 antibody seroprevalence (% seropositive) in blood donors 25
- Regional prevalence of infection over time 26
- Figure 4. 12-weekly rolling SARS-CoV-2 antibody seroprevalence (% seropositive) in blood donors by region, using Roche N test; error bars show 95% confidence intervals 26
- Table 10. Roche N seropositivity (95% CI) estimates by NHS region 27
- Prevalence by age group 28
- Figure 5. Population weighted 12-weekly rolling SARS-CoV-2 antibody seroprevalence (% seropositive) in blood donors from the Roche N assay by age group 28
- Table 11. Roche N seropositivity (95% CI) estimates by age group 29
- Roche S levels by age group and month 29
- Figure 7. Categorised Roche S antibody levels by age group and month in N positive samples, September 2022 to August 2023 31
- References 32
- About the UK Health Security Agency 35
